Patients Maintenance: The underexamined half of the GLP-1 story GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
News Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug... Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.
Digital Dr Craig Primack: How telehealth closes obesity care gaps What does Hims & Hers aspire to achieve as it enters into new markets? Dr Craig Primack discusses misinformation surrounding obesity and weight loss.
News More data backs Zepbound over Wegovy for weight loss Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.
Patients Beyond weight loss: Exploring the impact of weight loss medi... It’s been less than two years since weight loss medications Wegovy and Mounjaro were approved in the UK to treat obesity.
Market Access UK weight loss market: M&A opportunities Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.